Biocartis Group Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Roger Moody

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	6.9yrs
Promedio de permanencia en la Junta Directiva	5.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Roger Moody

less than a year

Permanencia

Mr. Roger Moody is Chief Executive Officer of Biocartis Group NV from April 24, 2023. Mr. Moody has experience in the technology and healthcare industry and brings a unique combination of deep knowledge of...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Piet Houwen	Chief Operating Officer	4.7yrs	sin datos	sin datos
Roger Moody	Chief Executive Officer	less than a year	sin datos	sin datos
George Cardoza	CFO & Head of Service Delivery	less than a year	sin datos	sin datos
Benoit Devogelaere	Chief Technology Officer	6yrs	sin datos	sin datos
Geert Maertens	Chairman of Scientific Advisory Board & Chief Scientific Officer	no data	sin datos	sin datos
Renate Degrave	Head of IR & Corporate Communications	no data	sin datos	sin datos
Susy Spruyt	Head of People & Organization	8.9yrs	sin datos	sin datos
Erwin Sablon	Head of R&D and Alliance Management	11.3yrs	sin datos	sin datos
Reginald Van Genechten	Head of Manufacturing & Supply Chain	7.8yrs	sin datos	sin datos
Erik Vossenaar	Vice President of Business Development	7.9yrs	sin datos	sin datos

6.9yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 8XB es experimentado (6.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Geert Maertens	Chairman of Scientific Advisory Board & Chief Scientific Officer	no data	sin datos	sin datos
Christian Reinaudo	Independent Director	5.6yrs	€84.00k	sin datos
Herman Verrelst	Independent Chairman of the Board	6.3yrs	€436.78k	sin datos
Jean-Louis Vincent	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ann-Christine Sundell	Non Executive Independent Director	5.9yrs	€47.50k	sin datos
Pasi Antero Janne	Member of Scientific Advisory Board	no data	sin datos	sin datos
Alberto Bardelli	Member of Scientific Advisory Board	no data	sin datos	sin datos
Eric Cutsem	Member of Scientific Advisory Board	no data	sin datos	sin datos
Josep Tabernero	Member of Scientific Advisory Board	no data	sin datos	sin datos
Bert Niesters	Member of Scientific Advisory Board	no data	sin datos	sin datos
Luc Gijsens	Non-Executive Independent Director	5.9yrs	€49.50k	sin datos
Michael Press	Member of Scientific Advisory Board	no data	sin datos	sin datos

5.9yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de 8XB se considera experimentada (5.9 años de antigüedad promedio).

Biocartis Group Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings released: €1.24 loss per share (vs €1.11 loss in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.31

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

Revenue beats expectations

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

New 90-day low: €3.92

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad